Osteoporosis Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends & Forecast 2018 - 2026

For the historical period 2017–2018 and the forecast period 2018–2026, the worldwide Osteoporosis Treatment Market is expected to be driven by rising osteoporosis prevalence, a growing ageing population that is more susceptible to osteoporosis, and the launch of innovative therapeutics.

The global osteoporosis medications market was valued at US$ 11.5 billion in 2018, according to the report, and is expected to decline at a CAGR of 0.3 percent from 2019 to 2027.

Osteoporosis has a high incidence and prevalence, which is exacerbated by the growing senior population.

The rising prevalence of osteoporosis is seen as a key market driver, since more patients mean greater need for the treatments. Furthermore, due to the lack of a viable alternative, such as surgery, demand for osteoporosis medications is steadily increasing.

According to the International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures each year, with an osteoporotic fracture occurring every 3 seconds, and it affects 200 million women worldwide.

Furthermore, the growing geriatric population is seen as a key driver of market growth in the approaching years. Due to hormonal changes, people over the age of 50 are at the greatest risk of developing osteoporosis and accompanying fractures.

Blockbuster medication patents expiring and dynamic pricing fluctuations due to generics limit market expansion.

The Osteoporosis Treatment Market is hampered by patent expiration and loss of exclusivity. Because generic copies of branded pharmaceuticals are made and marketed for 1/10th the price of the original branded drug, a branded drug's loss of patent exclusivity results in a severe revenue fall of nearly 35 percent to 40% in the first year.

Although generic medications are unable to match or exceed the overall sales of branded formulations, their reduced cost leads to increased usage.